je.st
news
Tag: pediatric
Amarantus Requests Rare Pediatric Disease Designation From FDA
2016-02-09 01:17:54| drugdiscoveryonline News Articles
Amarantus BioScience Holdings, Inc.(OTCQB: AMBS),a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration (FDA) for treating retinitis pigmentosa (RP) with MANF.
Tags: disease
requests
rare
designation
MRI Interventions to Exhibit the ClearPoint Neuro Navigation System at AANS/CNS Section on Pediatric Surgery
2015-12-10 11:31:11| Industrial Newsroom - All News for Today
IRVINE, Calif., MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint Neuro Navigation System will be on exhibit at the Annual Meeting of the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Pediatric Surgery, taking place on December 8...
Tags: system
navigation
section
surgery
Innovative and Realistic Gaumard Adult, Pediatric and Neonatal Simulators to be Showcased at the American Heart Association Scientific Sessions 2015
2015-11-11 11:31:12| Industrial Newsroom - All News for Today
Company to Demonstrate its AHA CPR/ECC Guideline-Compliant Simulators MIAMI - Gaumard Scientific Company today announced that it will provide demonstrations of its innovative HAL patient simulators and Newborn Tory at the American Heart Association Scientific Sessions 2015 from Nov. 8-10 in Orlando, Fla. Gaumard's...
Tags: american
heart
association
adult
A Pediatric Endocrinologist's View Of MannKind's Afrezza
2015-11-05 13:08:14| Biotech - Topix.net
There have been many investment analyst opinions expressed about the coming success or failure of MannKind Corporation's new inhaled insulin, Afrezza. Sanofi , MannKind's pharmaceutical marketing partner, has invested millions of dollars in up front licensing fees, milestone payments, and Afrezza related costs in marketing and promotion.
FDA Approves Pediatric Indication for EMEND (aprepitant) Capsules in Combination with Other Antiemetic Agents
2015-09-02 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for EMEND (aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor antagonist. Language: English Contact: MerckMedia:Doris Li, 908-740-1903An Phan, 908-255-6325orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: combination
agents
indication
pediatric